AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD). 

Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data emerging from the Phase II VacSYn trial of ACI-7104.056 active immunotherapy in early Parkinson’s disease. These additional interim safety and immunogenicity data after six months of treatment underscore the good safety profile and reinforce the best-in-class characteristics of ACI-7104.056 for the treatment of Parkinson’s disease. We look forward to sharing further updates later in 2025.” 

VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase II study in patients with early PD, consisting of two parts with a seamless transition.  

Part one includes initial analyses from over 30 patients randomised to receive ACI-7104.056 or placebo at a ratio of 3:1.  

To date, in the blinded, pooled active and placebo groups, no serious adverse event considered related to the study drug has been reported. 

Interim results show positive antibody responses were effectively induced against the target antigen at week six after two immunisations and were further boosted by each additional immunisation.  

Treatment with ACI-7104.056 induced an increase in anti-a-syn antibodies on average over 20-fold higher than the placebo background level after four immunisations. 

Based on further interim results to be reported later in 2025, AC Immune could initiate part two of VacSYn with up to 150 patients.  

Further exploratory endpoints for patients in part two will include the evaluation of the progression of motor and non-motor symptoms of the disease, as well as digital, imaging, and fluid biomarkers.  

The aim is to establish early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study.

Diana Spencer, Senior Digital Content Editor, DDW